

Medical Cannabis Conundrums

Wayne Hall

The University of Queensland Centre
for Clinical Research

Context

- By-product of policy debate about cannabis use
 - no “medical marijuana” debate if cannabis were legal
- Polarisation of policy debate:
 - Reformers support medical uses of marijuana
 - Prohibitionists oppose any medical use
 - Difficulties in finding a policy compromise
- Literature dominated by partisans
 - Opponents of any medical cannabinoid use
 - Proponents of “medical marijuana” as a panacea

Key Questions

- Do cannabinoids have medical uses?
- Are pharmaceutical cannabinoids the solution?
- Should cannabis be smoked for medical purposes?
- If so, how can this be done given:
 - the prohibition on recreational use
 - pharmaceutical regulatory requirements
 - issues of equity in funding medical treatments?

Defining some key terms

- Cannabis: any product of *cannabis sativa*
 - Marijuana: flowering tops
 - Hash: compressed resin
 - Cannabis extracts e.g. Sativex
- Cannabinoids for potential medical use:
 - Cannabis extracts e.g. Sativex (THC:CBD)
 - Drugs derived from cannabis plants (THC/CBD)
 - Synthetic drugs that act on cannabinoid receptors
 - agonists or antagonists

Medical Uses of Cannabinoids

- **Major uses for symptom relief**
 - Usually as an adjunctive or second line treatment
- **Major putative medical benefits :**
 - controlling nausea and vomiting *
 - Stimulating appetite *
 - reducing muscle spasticity & pain in MS *
 - reducing intraocular pressure in glaucoma
 - chronic pain

Nausea and Vomiting

- **Older indication with evidence of efficacy:**
 - RCTs conducted in 1970s and 1980s
- **THC had anti-emetic effects**
 - compared to prochlorperazine
 - anti-emetic effects of THC modest (30% control of emesis)
 - newer drugs much more effective (90% control of emesis)
 - with fewer side-effects including psychoactive ones
- **Smoked cannabis**
 - much weaker evidence
 - very limited use in intractable cases

Wasting Syndrome & Anorexia

- **Cannabis in AIDS-related wasting**
 - anecdotal evidence of benefit from smoking cannabis
 - AIDS advocacy groups campaigned for right to use
- **Dronabinol approved by FDA for this use 1985**
 - but limited use: difficulties titrating dose & side effects
 - Cochrane review concluded evidence weak
- **Main role as an adjunctive treatment**
 - Little used now because of advent of HART
 - Few HIV infected persons progress to clinical AIDS

Neurological Disorders

- Treat muscle spasticity & neuropathic pain in MS
- Sativex: a medical extract from cloned cannabis plants
 - One with high THC and one with high CBD
 - Combined to produce a THC:CBD ratio of 1:1
 - Delivered by oromucosal spray under the tongue
- Rationale:
 - Quality controlled defined dose of THC:CBD
 - CBD to moderate psychoactive effects of THC
 - Avoids smoking as a route of administration
 - Method of production patentable

Meta-analysis of Trials in Neuropathic Pain

- Iskedjian et al (2007) funded by GW
 - 6 studies with 298 patients
- Significant reduction in pain for all cannabinoids
 - 1.5 points on 10 point scale vs 0.8 for placebo
- Clinical significance?
 - Usually 2 point reduction required for “significance”
 - Little evidence of objective motor improvement

Acute Risks

(e.g. if used as an anti-emetic)

- Major risk: impaired psychomotor performance
 - Increased risk if patients drive: advise them not to drive
- “Within limits tolerated for medications” (IOM, 1999)
when used for:
 - for short periods of time
 - in the absence of major contraindications
- Low rate of adverse events in Sativex trials
 - Dizziness the most common
 - Fewer adverse psychoactive effects
 - Low rating of “high”

Risks of Chronic Cannabis Use?

- Know most about adverse effects of recreational use:
 - Smoked cannabis in adolescents and young adults
- Uncertain how relevant these risks to medical use
 - In middle-aged and older adults with chronic illnesses
- Major Health Risks of possible relevance:
 - Dependence?
 - Myocardial infarction in high risk adults, if smoked?
 - Chronic bronchitis & possible malignancy, if smoked?

Are Pharmaceutical Cannabinoids the Answer?

- **THC registered as Dronabinol or Marinol**
 - Required public investment by NIH
 - THC is not patentable so orphan drug
- **But not widely used**
 - Oral route not well suited to THC
 - Difficult to titrate dose
 - High rates of adverse psychoactive effects
- **Sativex the current best hope**
 - Registered for MS in Canada, UK and parts of Europe
 - Will it be more acceptable than dronabinol?

Should we allow cannabis to be smoked for medical purposes?

- Why may we want to do so?
 - If Sativex is not used by patients
- Decriminalize medical use of marijuana
 - for specified medical indications
- Challenges:
 - Enforcement issues for police
 - Where do patients obtain their cannabis?
 - Equity issues raised by special access schemes

US Medical Marijuana Initiatives

- Citizen initiated referendum to allow medical marijuana
 - California 1996; 9 other US states since then
- In CA illicitly grown cannabis supplied via “compassion’ clubs” to patients
 - with a recommendation from a medical practitioner
 - that patient has a condition that “may benefit from” cannabis
- Problems:
 - looseness of criteria: de facto legalisation in CA
 - Conflict between Federal and State laws
 - Continued uncertainty for patients and prescribers

Who Uses Medical Marijuana in California?

- Medical cannabis patients in SFO Bay Area 2001-2007
 - O'Connell and Bou-Matar (2007) N = 4117
- Characteristics:
 - 77% male; average age: 32 years
 - 89% had used cannabis before 19
 - 90% daily smokers of 1/8 to 1/4 oz/week
 - Indications?
 - Given age unlikely to be AIDS, cancer or neurological diseases
 - Harm reduction for alcohol and other drug use disorders?
- A de facto marijuana maintenance program?

Canada's Medical Cannabis Program

- Since 1999 patients allowed
 - to possess and grow cannabis for their own use
 - Carers can do so if patients unable to do so
- Problems:
 - Reluctance of physicians to prescribe
 - Patient complaints about cannabis quality & cost
 - Low uptake and C\$30M for 1900 patients since 1999
 - Equity of access to pharmaceuticals
 - Unapproved drug of uncertain safety and efficacy
 - When drugs of known efficacy are not subsidised

Medical Cannabis in the Netherlands

- Legal supply of medical cannabis by government
 - On prescription and dispensed by pharmacists
- Interesting policy setting
 - Cannabis use decriminalized since early 1970s
 - De facto retail cannabis market in coffee shops
- How much patient interest is there in medical use of cannabis if recreational use is effectively legal?

Medical Use in the Netherlands

- Survey of Dutch 5,540 medical cannabis patients 2003-2010
 - Hazekamp and Heerdink (2013)
- Incidence:
 - 6 per 100,000 for 2003-2004
 - 2 per 100,000 for 2005-2010
- Prevalence:
 - 5-8 vs 100 per 100,000 in some states in USA
- Indications (based on co-prescribed medications):
 - Pain (54%)
 - Cancer (3%)
 - HIV (1%)

Medical Cannabis Conundrums 1

- If cannabis is illegal it can only be prescribed
 - if approved by the regulatory system and
 - a company is prepared to supply it
- Smoked cannabis:
 - Unlikely to be approved for medical use
 - No financial incentive for companies to register
- So governments have created special access schemes
 - Ignored regulatory requirements & subsidized supply
 - Creating a worrisome precedent and
 - Raising equity issues

Medical Cannabis Conundrums 2

- Disincentives for pharma to develop new cannabinoids:
 - Patentability, profitability and regulatory burdens
- Approved medicinal cannabinoids not very popular
 - Dronabinol neither widely used nor profitable
- Sativex the current best hope:
 - But small market and modest efficacy to date
 - Will it prove acceptable
 - to patients and “medical marijuana” advocates?

Medical Cannabis Conundrums 3

- If medical cannabis use is legally allowed
 - Medical users need not fear prosecution
 - Reluctance of physicians to prescribe
 - But legal supply remains a problem
 - Unless Governments allow cultivation or supply it
 - If governments provide, an expensive program
 - Equity issues in providing unapproved drug